AIM ImmunoTech announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen as a potential treatment for Myalgic encephalomyelitis/chronic fatigue syndrome and Long COVID. Dr. Lapp has played a key role in AIM‘s long-standing AMP-511 Expanded Access Program for the treatment of ME/CFS and Long COVID, having founded one of the clinical trial’s key sites, the Hunter-Hopkins Center in Charlotte, N.C., from which he recently retired.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
- AIM ImmunoTech announces interim report data from Ampligen study
- AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
